Jennifer Kamocsay - Feb 22, 2024 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role
General Counsel
Signature
/s/ Jennifer Kamocsay, by Brian McKelligon, as Attorney-in-Fact
Stock symbol
AKYA
Transactions as of
Feb 22, 2024
Transactions value $
-$19,796
Form type
4
Date filed
3/1/2024, 09:53 PM
Previous filing
Nov 27, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKYA Common Stock Award $0 +35K +51.85% $0.00 103K Feb 22, 2024 Direct F1, F2
transaction AKYA Common Stock Tax liability -$19.8K -3.28K -3.2% $6.03 99.2K Mar 1, 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKYA Employee Stock Option (Right to Buy) Award $0 +70K $0.00 70K Feb 22, 2024 Common Stock 70K $5.35 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units shall vest in four (4) equal annual installments beginning on March 1, 2025, and annually thereafter until fully vested.
F2 Each restricted stock unit represents a contingent right to receive one share of Akoya Biosciences, Inc. common stock.
F3 Represents shares withheld to cover taxes on a restricted stock unit award previously granted February 23, 2023, which vest in four (4) equal annual installments beginning on March 1, 2024, and annually thereafter until fully vested.
F4 The options shall vest as follows: twenty-five percent (25%) shall vest on February 22, 2025 with the remainder vesting in 36 equal monthly installments beginning on March 22, 2025.